Artivion (AORT) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $95.8 million, up 10% year-over-year in constant currency, with strong performance across On-X, BioGlue, stent grafts, and preservation services, and adjusted EBITDA grew 28% to $17.7 million.

• Net loss narrowed to $2.3 million, or $0.05 per share, compared to a $9.8 million loss last year; non-GAAP net income was $5.0 million, or $0.12 per share.

• Achieved regulatory milestones: BioGlue approved in China (commercialization expected H2 2025), first PMA module for AMDS submitted to FDA (approval anticipated Q4 2025), and NEXUS TRIOMPHE trial enrollment completed.

• Product portfolio, especially On-X, BioGlue, and stent grafts, delivered double-digit growth, with notable market share gains and successful international commercialization.

• Operating expenses decreased 2% for the quarter, mainly due to lower business development expenses.

Financial highlights

• Q3 2024 revenue was $95.8 million, up 10% year-over-year in constant currency; gross margin was 63.7%–64%.

• Adjusted EBITDA grew 28% to $17.7 million, with margin improving by 270–280 basis points to 18.5%.

• Free cash flow was $7.8 million; cash balance at quarter-end was $56.2 million, with $314 million in debt.

• Net loss for the quarter was $2.3 million; adjusted net income was $5.0 million.

• Operating income for the quarter was $4.4 million, compared to a loss of $1.2 million last year.

Outlook and guidance

• Full-year 2024 constant currency revenue growth expected at 10–12%, with revenue guidance narrowed to $389–$396 million.

• Adjusted EBITDA for 2024 projected at $69–$72 million, representing 28–34% growth and 280 basis points of margin expansion.

• Free cash flow positive for FY24 expected; net debt leverage targeted at ~3.5x.

• 2025 guidance to be provided in February; minimal AMDS revenue expected in 2025 due to launch timing.

• Negligible currency impact expected on 2024 revenues at current rates.